Shares

Servier cuts off collaboration agreement with Allogene on CD19 products, sending shares sputtering – Endpoints News

Al­lo­gene Ther­a­peu­tics said in an SEC fil­ing to­day that French part­ner Servi­er has cut off its in­volve­ment in a part­ner­ship de­vel­op­ing ther­a­pies di­rect­ed against CD19, in­clud­ing the most ad­vanced can­di­dates in Al­lo­gene’s pipeline.

Shares of Al­lo­gene $AL­LO, an out­fit run by Kite vets Arie Bellde­grun and re­search chief David Chang, fell by al­most 10% on Wednes­day, even as the San Fran­cis­co-based com­pa­ny said that Servi­er’s dis­con­tin­u­a­tion “does not oth­er­wise af­fect our cur­rent ex­clu­sive li­cense for the de­vel­op­ment and com­mer­cial­iza­tion of CD19 Prod­ucts in the Unit­ed States.”

Cut­ting of Servi­er will al­so al­low Al­lo­gene to li­cense these CD19 prod­ucts — AL­LO-501, AL­LO-501 and UCART19 — out­side of the US, with mile­stones of up to €46 mil­lion ($45 mil­lion).

Ex­er­cis­ing that ex-US op­tion, how­ev­er, which Servi­er wants done quick­ly, would cut off Al­lo­gene’s abil­i­ty to re­cov­er from Servi­er 40% of the de­vel­op­ment costs for CD19 prod­ucts.

Part of the rea­son for this sep­a­ra­tion may be Servi­er’s on­go­ing CD19-re­lat­ed col­lab­o­ra­tion with Cel­lec­tis. Un­der a 2014 deal, Cel­lec­tis re­ceived $10 mil­lion up­front and was el­i­gi­ble for up to $140 mil­lion to de­vel­op six prod­uct can­di­dates.

And while Servi­er has al­so cut off its work with Al­lo­gene, Cel­lec­tis “has chal­lenged cer­tain per­for­mance by Servi­er and has al­so chal­lenged the abil­i­ty of Servi­er to grant a world-wide sub­li­cense,” Al­lo­gene said in the SEC fil­ing.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.